Additionally, TAM-induced AKT phosphorylation is closely associated with HER-2 (59), suggesting that the use of HER-2 inhibitors may improve resistance to EGFR-TKIs in NSCLC (71, 72). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.